NCT06560645CompletedPhase 1
A Phase 1 Study of PRT7732, an Oral SMARCA2 Degrader, in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation
Source: EU CTIS (euclinicaltrials.eu) · Last updated 7 Oct 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- First submitted
- 20 Sept 2024
- Start date
- 3 Mar 2025
- Lead sponsor
- Prelude Therapeutics Inc.
- Diseases
- Lung cancer, Gastric and esophageal cancer
- NCT number
- NCT06560645
- EU CT number
- 2024-512380-32-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 16
- 5 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Cologne AöR Coordinator of this site? Confirm its status | Cologne | Germany | Completed |
| Technische Universitaet Dresden Coordinator of this site? Confirm its status | Dresden | Germany | Completed |
| Hospital Universitari Vall d'Hebron Coordinator of this site? Confirm its status | Barcelona | Spain | Completed |
| Hospital Universitario HM Sanchinarro Coordinator of this site? Confirm its status | Madrid | Spain | Completed |
| Hospital Universitario Fundación Jiménez Díaz Coordinator of this site? Confirm its status | Madrid | Spain | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.